AQUASNARE: Artificial-intelligence-based QUAntification of Size measuremeNts of Adenoma in Routine Endoscopy

Sponsor
Wuerzburg University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06040710
Collaborator
(none)
156
1
6
26.1

Study Details

Study Description

Brief Summary

Polyp size and count determines the follow-up intervals after colonoscopy. However, relying on the endoscopist's optical diagnosis for size estimation has shown considerable variability, leading to erroneous surveillance intervals and increased colorectal cancer risk. This study aims to assess the effectiveness of a new polyp size estimation software, called POSEIDON, which uses the tip of the auxiliary water-jet as reference and is implemented together with the EndoMind polyp detection system.

Condition or Disease Intervention/Treatment Phase
  • Device: POSEIDON size estimation software with the EndoMind polyp detection system

Detailed Description

Objective:

The primary aim of this study is to conduct a superiority analysis between POSEIDON and endoscopist optical estimation, focusing on the errors of polyp size measurement. Secondary objectives encompass subgroup analyses concerning varying polyp sizes and histology, potential impact on follow-up protocols based on polyp sizes, and determination of the percentage of cases where obtaining measurements with POSEIDON proves unfeasible.

Study Design:

Single center, endoscopist blinded study. Considering the results of the preliminary study, a total of 42 pairs of measurements suffices to extrapolate statistical significance for a power of 90% and a significance level of 0.05. Taking dropout rates, average number of polyps per patient, polyp detection rate, the number of patients expected to be enrolled for the study is 156. For obtaining the gold standard measurement, images from the examination recording where the tip of a snare is placed next to the polyp are extracted. The snare tip and polyp are manually segmented and their largest diameter in pixels is manually calculated. The diameter of the snare-tip will be measured after the examination to account for production based variations. Based on this, the gold standard polyp size is calculated.

AI setup and limitations:

The version of the polyp detection system, EndoMind, is an updated version of the one published in (PMID: 35543874). Notably, the POSEIDON method has undergone dual refinements from its first published version (PMID: 37080235). Firstly, the AI model for water-jet tip detection has been further trained using images from colonoscopy videos, leading to performance improvements. Secondly, the pixel-to-millimeter conversion methodology has been optimized to align with the specifications of the endoscopes employed in the trial.

To obtain a polyp size estimation, initially the polyp is detected by means of a bounding box through the EndoMind system. Then, once water-jet is sprayed next to the polyp, POSEIDON detects the tip of the water-jet, where it touches the mucosa. The coordinates of the tip in the endoscopic image are correlated to the distance of the endoscope to the mucosa. With the above, the largest diameter of the bounding box is converted from pixels to millimeters, resulting in the size estimation.

For measurement acquisition, the system is initiated at the beginning of the examination and deactivated at its conclusion, facilitated by a dedicated button press. Concerning expert-system interaction, the CADe system's identifications consistently appear on an auxiliary screen within the endoscopist's workspace. On this screen, precise visualization of the impact point between the water-jet beam and the mucosa follows water-jet detection. Subsequently, the endoscopist receives visual affirmation of a successful calculation of polyp size estimation, derived from the bounding box on the screen. The endoscopist evaluates the alignment of this box around the polyp to assess the accuracy measurement outcome. Importantly, throughout these operations, the endoscopist remains blinded to the size estimated by POSEIDON. The endoscopist also reports polyp cases where they are unable to obtain a proper measurement.

Study population:

All adult patients with screening or surveillance colonoscopies that do not match the exclusion criteria will be asked for informed consent. Up to 3 polyps per patient will be included in the final study.

Intervention:

Upon polyp identification by the endoscopist, the visual assessment will be conducted, followed by obtaining a satisfactory measurement using POSEIDON when possible, as described in the AI methods section. To eliminate potential learning bias and optimize efficiency, the examiner will be blinded to the immediate measurement result. Finally, after both measurements are obtained, an instrument tip of known size will be positioned adjacent to the polyp, which is to be later used for obtaining the gold-standard polyp size.

Study Design

Study Type:
Observational
Anticipated Enrollment :
156 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Artificial-intelligence-based QUAntification of Size measuremeNts of Adenoma in Routine Endoscopy
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Jan 31, 2024
Anticipated Study Completion Date :
Mar 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention arm

All patients within the study are included in the intervention arm: polyp detected within these patients will be measured according to the study protocol using two different methods.

Device: POSEIDON size estimation software with the EndoMind polyp detection system
Polyp size estimation using the POSEIDON software and bounding boxes of the EndoMind polyp detection system.

Outcome Measures

Primary Outcome Measures

  1. Size estimation error comparison for colorectal polyps using POSEIDON versus physician optical evaluation [Through study completion, an average of 5 months]

    The error between gold standard polyp size and estimation using POSEIDON and optical estimation will be compared in pairs for the same polyps. If more than three polyps are measured in the same examination, 3 of them are included.

Secondary Outcome Measures

  1. Size estimation error comparison for colorectal polyps using POSEIDON versus physician optical evaluation for different size categories [Through study completion, an average of 5 months]

    Polyps will be split into size categories based on national and international guidelines. The study will assess the errors of both POSEIDON and optical estimation within each group through pairwise comparison

  2. Size estimation error comparison for colorectal polyps using POSEIDON versus physician optical evaluation for polyps with different histologies [Through study completion, an average of 5 months]

    Polyps will be split into based on their histological evaluation. The study will assess the errors of both POSEIDON and optical estimation within each group through pairwise comparison.

  3. Guideline-suggested follow-up interval changes based purely on detected polyp size. [Through study completion, an average of 5 months]

    The study determines follow-up intervals based on three international standards, solely considering polyp size estimated by the two methods.

  4. Percentage of polyps where endoscopists failed to obtain POSEIDON measurement. [Through study completion, an average of 5 months]

    Evaluation of the percentage polyps for which the endoscopist was unable to obtain a proper measurement with the proposed method.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adult patients

  • Scheduled for colonoscopy

Exclusion Criteria:
Patient Level:
  • Inflammatory Bowel Disease

  • Familiar Polyposis Syndrome

  • Patient after radiation/resection of colonic parts

Data Level

  • Failure to initialize system before examination

  • Missing instrument placement next to polyp to obtain gold standard

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universitätsklinikum Würzburg Würzburg Bayern Germany 97080

Sponsors and Collaborators

  • Wuerzburg University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wuerzburg University Hospital
ClinicalTrials.gov Identifier:
NCT06040710
Other Study ID Numbers:
  • AI02
First Posted:
Sep 15, 2023
Last Update Posted:
Sep 15, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Wuerzburg University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 15, 2023